PHOTOLABILE SPATIAL LABEL GENERATION
    5.
    发明公开

    公开(公告)号:US20240318169A1

    公开(公告)日:2024-09-26

    申请号:US18737499

    申请日:2024-06-07

    CPC classification number: C12N15/1065 C12N15/1068

    Abstract: Disclosed herein are method for labeling analytes using spatial barcodes, illumination, and/or photolabile cross-linkers. The methods may generate a set of unique spatial barcodes using limited sets differential nucleotide sequences. The labeling may identify a spatial location of an analyte. Also provided herein are compositions, kits, or system for carrying out the methods.

    ADAPTIVE BASE CALLING SYSTEMS AND METHODS
    7.
    发明公开

    公开(公告)号:US20240249797A1

    公开(公告)日:2024-07-25

    申请号:US18424587

    申请日:2024-01-26

    CPC classification number: G16B30/00 C12Q1/6874 G16B40/20

    Abstract: Methods for updating a system comprising a sequencer are described herein. In some exemplary methods, the system is updated through generating sequencing data for a plurality of nucleic acid molecule colonies, selecting sequencing data for a subset of the nucleic acid molecule colonies, calling preliminary sequences for the subset of the nucleic acid colonies, mapping the called preliminary sequences to a known reference sequence, and updating the pre-trained sequencer-specific machine-learning model. Also described herein are systems for carrying out such methods and computer readable memory for storing such methods.

    METHODS AND SYSTEMS FOR DETECTING RESIDUAL DISEASE

    公开(公告)号:US20240018599A1

    公开(公告)日:2024-01-18

    申请号:US18035075

    申请日:2021-11-17

    CPC classification number: C12Q1/6886 C12Q1/6827 C12Q2600/112

    Abstract: Described herein are methods, devices, and systems for measuring a level, presence, recurrence, progression, or regression of a disease (such as cancer), for example a fraction of nucleic acid molecules (such as cell-free DNA) in a sample from an individual that relate to diseased tissue (such as cancer tissue). The methods include generating, using the sequencing data comprising sequencing reads associated with loci selected from a personalized disease-associated small nucleotide variant panel, a plurality of variant motif-specific models that each associate sequencing data corresponding to a respective variant motif, a background factor indicative of a false positive error rate for the respective variant motif, and an estimated fraction of the nucleic acid molecules associated with the disease. From the plurality of variant motif-specific models, a fraction of the nucleic acid molecules associated with the disease for the individual can be determined.

Patent Agency Ranking